Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background Multiple sclerosis is an inflammatory disease of the central nervous system that destroys myelin, oligodendrocytes, and axons. Since most of the lesions of multiple sclerosis are not remyelinated, enhancement of remyelination is a possible therapeutic strategy that could perhaps be achieved with the transplantation of oligodendrocyte-producing cells into the lesions. We investigated the frequency distribution and configuration of oligodendrocytes in chronic lesions of multiple sclerosis to determine whether these factors limit remyelination. Methods Forty-eight chronic lesions obtained at autopsy from 10 patients with multiple sclerosis were examined immunocytochemically for oligodendrocytes and oligodendrocyte progenitor cells. Using confocal microscopy, we examined the three-dimensional relations between axons and the processes of premyelinating oligodendrocytes. Results Thirty-four of the 48 chronic lesions of multiple sclerosis contained oligodendrocytes with multiple extended processes that associated with demyelinated axons but failed to myelinate them. These axons were dystrophic and contained multiple swellings. In some regions, the densities of premyelinating oligodendrocytes (25 per square millimeter of tissue) were similar to those in the developing rodent brain (23 per square millimeter). In the patients with disease of long duration (more than 20 years), there were fewer lesions with premyelinating oligodendrocytes (P Conclusions Premyelinating oligode…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The efficacy of remyelination has been shown to depend on multiple factors such as, age, disease duration and lesion location.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [12]
In the citing paper
“The long‐term consequence of demyelination in the CNS is axonal damage and neurodegeneration (Chang et al. 2002) in both white and gray matter lesions, leading to progressive disease.”
From Depletion of Microglia Increases Cortical Oligodendrocyte Density During Remyelination (2026) · cites this paper as Chang et al. 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“Furthermore, oligodendrocyte progenitor cells (OPCs) are a population of adult stem cells responsible for mediating CNS myelin repair in demyelinating conditions such as MS [113,114].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [114]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Self-citationNoseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Raff, M. C., Miller, R. H., & Noble, M. (1983) · Nature · doi:10.1038/303390a0 · Cited by 2,030
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Cell death and control of cell survival in the oligodendrocyte lineage
Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T., Richardson, W. D., & Raff, M. C. (1992) · Cell · doi:10.1016/0092-8674(92)90531-g · Cited by 1,345
Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis
Kornek, B., Storch, M. K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T., Linington, C., Schmidbauer, M., & Lassmann, H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64537-3 · Cited by 921
The oligodendrocyte and its many cellular processes
PFEIFFER, S., WARRINGTON, A., & BANSAL, R. (1993) · Trends in Cell Biology · doi:10.1016/0962-8924(93)90213-k · Cited by 737
NG2-Positive Oligodendrocyte Progenitor Cells in Adult Human Brain and Multiple Sclerosis Lesions
Chang, A., Nishiyama, A., Peterson, J., Prineas, J., & Trapp, B. D. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06404.2000 · Cited by 712
Self-citation
Research works printed but not linked: 2
- 10.1056/nejm199801293380610 · doi:10.1056/nejm199801293380610 · Paper page
- Prineas JW, 1989, Lab Invest, 61, 489
Cited by
Items 601–700 of 1,000
Della-Flora Nunes, G., Osso, L. A., Haynes, J. A., Conant, L., Thornton, M. A., Stockton, M. E., Brassell, K. A., Morris, A., Mancha Corchado, Y. I., Gaynes, J. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56092-6 · Cited by 19
Promoting remyelination for the treatment of multiple sclerosis: opportunities and challenges
Zhang, Y., Guo, T. B., & Lu, H. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1317-z · Cited by 21
Oligodendrocytes Development and Wnt Signaling Pathway
Soomro, S. H., Jie, J., & Fu, H. Q. (2018) · International Journal of Human Anatomy · doi:10.14302/issn.2577-2279.ijha-18-2407 · Cited by 19
Gavriilaki, M., Sakellari, I., Gavriilaki, E., Kimiskidis, V. Κ., & Anagnostopoulos, Α. (2019) · Stem Cells International · doi:10.1155/2019/5840286 · Cited by 20
“Third, OPCs are already present in chronic lesions of MS, indicating that remyelination is rather limited by other factors, such as their interaction with the axons and the microenvironment [78].”
BackgroundHuang, Y., Song, Y. J., Isaac, M., Miretzky, S., Patel, A., McAuliffe, W. G., & Dreyfus, C. F. (2020) · ASN NEURO · doi:10.1177/1759091420957464 · Cited by 19
“, 2008), and the failure of premyelinating OLGs to myelinate axons (Chang et al., 2002).”
BackgroundLessons from oligodendrocyte biology on promoting repair in multiple sclerosis
Câmara, J., & ffrench‐Constant, C. (2007) · Journal of Neurology · doi:10.1007/s00415-007-1004-y · Cited by 20
Remyelination-Promoting Human IgMs: Developing a Therapeutic Reagent for Demyelinating Disease
Warrington, A. E., & Rodriguez, M. (2007) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-73677-6_9 · Cited by 19
“However, despite ineffective remyelination in MS, an abundant population of potential replacement cells, oligodendrocytes and their progenitors, are present even in chronic MS lesions [29, 30, 103, 170].”
BackgroundGharibi, T., Kazemi, T., Aliparasti, M. R., Farhoudi, M., Almasi, S., Dehghanzadeh, R., Seyfizadeh, N., & Babaloo, Z. (2015) · PubMed · Cited by 25
Magy, L., Mertens, C., Avellana‐Adalid, V., Keita, M., Lachapelle, F., Nait‐Oumesmar, B., Fontaine, B., & Evercooren, A. B. (2003) · Experimental Neurology · doi:10.1016/j.expneurol.2003.08.019 · Cited by 23
Inflammation and Remyelination in the Central Nervous System
Ruffini, F., Kennedy, T. E., & Antel, J. P. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63709-1 · Cited by 19
“OGC progenitor cells are found in MS lesions, as defined by morphology and cell surface molecule expression criteria.(10,11) The studies of Chang et al(10) showing abundant numbers of progenitor cells even in chronic MS lesions, emphasize the issue that factors other than progenitor numbers alone contribute to the ext…”
BackgroundThe Lesions of Multiple Sclerosis
Paty, D. W., & Arnold, D. L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201173460311 · Cited by 22
Li, L., Li, D., Sun, D., Zhang, X., Lei, W., Wu, M., Huang, Q., Nian, X., Dai, W., Lu, X., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.09.002 · Cited by 18
Fressinaud, C., & Eyer, J. (2013) · Journal of Neuroscience Research · doi:10.1002/jnr.23308 · Cited by 18
“It has been proposed that these alterations might, in turn, render axons improper for remyelination (Chang et al., 2002).”
BackgroundFeliú, A., Mestre, L., Carrillo-Salinas, F. J., Yong, V. W., Mecha, M., & Guaza, C. (2020) · Glia · doi:10.1002/glia.23775 · Cited by 18
“It appears that this failure of remyelination is not generally due to a loss of oligodendrocytes at the demyelinated MS lesions, the CNS cells that produce myelin (Chang et al., 2002, 2012), but rather, to an impediment in the successful remyelination of damaged axons (Franklin, 2002).”
BackgroundSato, N., Seiwa, C., Uruse, M., Yamamoto, M., Tanaka, K., Kawakita, T., Komatsu, Y., Yasukawa, A., Takao, M., Kudo, C., et al. (2010) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/neq001 · Cited by 18
“Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2011, Article ID 617438, 9 pages doi:10.1093/ecam/neq001”
InfluentialReduced production of noggin by immune cells of patients with relapsing–remitting multiple sclerosis
Urshansky, N., Mausner-Fainberg, K., Auriel, E., Regev, K., Bornstein, N. M., & Karni, A. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.10.007 · Cited by 18
“The presence of OPCs and premyelinating oligodendrocytes in chronic lesions of MS suggests that remyelination is most vulnerable during the differentiation rather than the recruitment phase (Wolswijk, 1998; Chang et al., 2002; Kuhlmann et al., 2008).”
BackgroundAxon cytoskeleton proteins specifically modulate oligodendrocyte growth and differentiation in vitro
Fressinaud, C., Bergès, R., & Eyer, J. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.10.011 · Cited by 20
Ljubisavljević, S., Stojanović, I. R., Bašić, J., & Pavlović, D. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9639-z · Cited by 18
“The question that remains open is whether NF phosphorylation is considered to be only a pathological consequence of the neural tissue damage or it has some other protective effects (Chang et al. 2002; Dale and Garcia 2012; Fressinaud et al. 2012).”
Gene discovery and validation for neurodegenerative diseases
Mathisen, P. M. (2003) · Drug Discovery Today · doi:10.1016/s1359644602025400 · Cited by 20
Stem cell therapy for central nervous system demyelinating disease
Manganas, L. N., & Maletić‐Savatić, M. (2005) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-005-0050-z · Cited by 19
Glial grafting for demyelinating disease
Tepavčević, V., & Blakemore, W. F. (2005) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2005.1700 · Cited by 19
“…mismatch between demyelination and the interaction of OPCs with demyelinated axons (Blakemore et al. 2002) and (iii) the observation that OPCs and premyelinating oligodendrocytes can be found in some areas of chronic demyelination in MS without evidence of remyelination (Chang et al. 2000, 2002).”
In situ characterisation of oligodendrocyte progenitor cells in adult mammalian optic nerve
Jennings, A. R., Kirilak, Y., & Carroll, W. M. (2002) · Journal of Neurocytology · doi:10.1023/a:1022567414294 · Cited by 20
Re-defining progression in multiple sclerosis
Lambe, J., & Ontaneda, D. (2025) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001369 · Cited by 18
Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis
Pan, S., & Chan, J. R. (2021) · Annals of Neurology · doi:10.1002/ana.26196 · Cited by 19
“signifying a need to explicitly target mechanisms that promote their differentiation and maturation.(17) In this”
BackgroundInfluentialCaillava, C., & Evercooren, A. B. (2012) · Cell Division · doi:10.1186/1747-1028-7-14 · Cited by 17
“Among several possible hypotheses, dysregulation of OPC proliferation has been proposed to play a role in remyelination failure, as demonstrated by reduced OPC proliferation in some lesions, although in others OPCs are numerous, but appear unable to fully differentiate [63].”
BackgroundAn in vitro model for studying CNS white matter: functional properties and experimental approaches
Bijland, S., Thomson, G., Euston, M., Michail, K., Thümmler, K., Mücklisch, S., Crawford, C. L., Barnett, S. C., McLaughlin, M., Anderson, T. J., et al. (2019) · F1000Research · doi:10.12688/f1000research.16802.1 · Cited by 19
“, 2010), which are often abundant in MS lesions but fail to myelinate the naked axons (Chang et al., 2000; Chang et al., 2002; Scolding et al., 1998).”
BackgroundCosenza, M., Zhao, M., Shankar, S. L., Shafit‐Zagardo, B., & Lee, S. C. (2002) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2002.00420.x · Cited by 17
Calcium control of myelin sheath growth
Miller, R. H. (2017) · Nature Neuroscience · doi:10.1038/s41593-017-0043-7 · Cited by 18
BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis
Bergner, C. G., van der Meer, F., Franz, J., Vakrakou, A., Würfel, T., Nessler, S., Schäfer, L., Nau-Gietz, C., Winkler, A., Lagumersindez-Denis, N., et al. (2025) · Brain · doi:10.1093/brain/awae293 · Cited by 20
Shim, G., Romero-Morales, A. I., Sripathy, S. R., & Maher, B. J. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1322813 · Cited by 17
Morita, S., Tatsumi, K., Makinodan, M., Okuda, H., Kishimoto, T., & Wanaka, A. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1190-1 · Cited by 16
“Although the reasons for remyelination failure in myelin disorders are unknown [8], the identification of oligodendrocyte progenitor cells within demyelinated lesions suggests a critical regulatory mechanism in the inhibition of oligodendrocyte progenitor cell differentiation, preventing their maturation to myelin-for…”
Cardona, J. G., Smith, M. D., Wang, J., Kirby, L. A., Schott, J. T., Davidson, T. S., Karnell, J. L., Whartenby, K. A., & Calabresi, P. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221747 · Cited by 16
Nheu, D., Ellen, O., Ye, S., Öztürk, E., Pagnin, M., Kertadjaja, S., Theotokis, P., Grigoriadis, N., McLean, C., & Petratos, S. (2022) · Cells · doi:10.3390/cells11233768 · Cited by 17
Proteomic strategies in multiple sclerosis and its animal models
Elkabes, S., & Li, H. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200700315 · Cited by 17
“Although adult oligodendrocyte progenitor cells are present in the multiple sclerosis brain, and immature or even myelin-producing mature oligodendrocytes are found in white matter lesions, proper remyelination of axons is unsuccessful especially at later disease stages [3, 4].”
Delayed Onset of Experimental Autoimmune Encephalomyelitis in Olig1 Deficient Mice
Guo, X., Harada, C., Namekata, K., Mitamura, Y., Yoshida, H., Matsumoto, Y., & Harada, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013083 · Cited by 16
Cid, C., Regidor, I., & Alcázar, A. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.001 · Cited by 16
Urshansky, N., Mausner-Fainberg, K., Auriel, E., Regev, K., & Karni, A. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.08.003 · Cited by 16
“Although both neural precursor cells (NPCs) and oligodendrocyte precursor cells (OPCs) are abundantly present in MS lesions (Wolswijk, 1998; Chang et al., 2002; Snethen et al., 2008), their differentiation into functional neurons and oligodendrocytes is mostly inconsistent, and many lesions fail to…”
Scheinok, T. J., D’Haeseleer, M., Nagels, G., De Bundel, D., & Van Schependom, J. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102459 · Cited by 16
Sarrazin, N., Chavret-Reculon, E., Bachelin, C., Felfli, M., Arab, R., Gilardeau, S., Brazhnikova, E., Dubus, E., Yahia Cherif, L., Lorenceau, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2115973119 · Cited by 15
Choi, B. Y., Jeong, J. H., Eom, J.-W., Koh, J., Kim, Y. H., & Suh, S. W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093375 · Cited by 17
“Furthermore, failed remyelination may be a consequence of persistent BBB permeability-mediated astrogliosis—preventing oligodendrocyte precursors (OPCs) from accessing the destroyed myelin—rather than an actual deficiency of OPCs, in late-stage lesions [35,36].”
BackgroundRahimirad, S., Navaderi, M., Alaei, S., & Sanati, M. H. (2021) · Neurological Sciences · doi:10.1007/s10072-020-04979-1 · Cited by 15
Pleshinger, M. J. A., Friedrich, R. M., Hubler, Z. M. L., Rivera-León, A. M., Gao, F., Yan, D., Sax, J. L., Srinivasan, R., Bederman, I. R., Shick, H. E., et al. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00145k · Cited by 15
Oligodendrocyte Lineage Cells in Chronic Demyelination of Multiple Sclerosis Optic Nerve
Jennings, A. R., & Carroll, W. M. (2014) · Brain Pathology · doi:10.1111/bpa.12193 · Cited by 15
“Recently, it has been reported that some chronic demyelination lesions in the brain and spinal cord contained immature phenotype oligodendrocyte lineage cells (14, 34, 39, 58, 59, 61).”
BackgroundResultInfluentialZhu, Y., Wendler, C. C., Shi, O., & Rivkees, S. A. (2014) · Brain Research · doi:10.1016/j.brainres.2014.08.046 · Cited by 15
“However, the differentiation of OPCs into myelinating oligodendrocytes may be impaired (Jablonska et al., 2012; Segovia et al., 2008), contributing to white matter injury (Alix et al., 2012; Chang et al., 2002; Kuhlmann et al., 2009).”
Cell-Based Reparative Therapies for Multiple Sclerosis
Ben‐Hur, T., Fainstein, N., & Nishri, Y. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0397-5 · Cited by 17
“The significant variability in pathological patterns of disease [26] and the eventual failure of remyelination in chronic MS in the face of abundant OPCs in the surrounding tissue [27–31] highlight the important role of the brain environment in dictating the feasibility of remyelination.”
TIP30 inhibits oligodendrocyte precursor cell differentiation via cytoplasmic sequestration of Olig1
Yang, W., Xiao, L., Li, C., Liu, X., Liu, M., Shao, Q., Wang, D., Huang, A., & He, C. (2014) · Glia · doi:10.1002/glia.22778 · Cited by 15
“…various demyelinating diseases such as multiple sclerosis (MS), is mainly due to the failure of OPCs to achieve terminal differentiation (Boulanger and Messier, 2014; Chang et al., 2000, 2002; Kremer et al., 2009; Kuhlmann et al., 2008; Scolding et al., 1998; Taveggia et al., 2010; Wolswijk, 1998).”
Chemokines Referee Inflammation within the Central Nervous System during Infection and Disease
Durrant, D. M., Williams, J. L., Daniels, B. P., & Klein, R. S. (2014) · Advances in Medicine · doi:10.1155/2014/806741 · Cited by 17
New insights into an old story: Pollen ROS also play a role in hay fever
Speranza, A., & Scoccianti, V. (2012) · Plant Signaling & Behavior · doi:10.4161/psb.20674 · Cited by 18
Multiple Sclerosis CD49d+CD154+ As Myelin-Specific Lymphocytes Induced During Remyelination
Piątek, P., Namiecińska, M., Domowicz, M., Wieczorek, M., Michlewska, S., Matysiak, M., Lewkowicz, N., Tarkowski, M., & Lewkowicz, P. (2019) · Cells · doi:10.3390/cells9010015 · Cited by 15
“Slow but constant progression of the disease is caused by inefficient and only partial regeneration of the myelin sheath around the neuronal axons after primary attack or relapse [4]; what still remains is the unsolved aspect of MS pathology.”
BackgroundSpontaneous remyelination following prolonged inhibition of α4 integrin in chronic EAE
Piraino, P. S., Yednock, T. A., Messersmith, E. K., Pleiss, M. A., Freedman, S. B., Hammond, R. R., & Karlik, S. J. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.06.018 · Cited by 17
“Recent evidence has shown that MS lesions contain substantial numbers of premyelinating oligodendrocytes (Wolswijk, 1998, 2002; Chang et al., 2000, 2002; Maeda et al., 2001; Solanky et al., 2001), and consequently that the potential for repair is not limited by a loss of these cells.”
BackgroundPathology of Neurons in Multiple Sclerosis
Lassmann, H. (2005) · Elsevier eBooks · doi:10.1016/b978-012738761-1/50012-2 · Cited by 17
Remyelination by Endogenous Glia
Franklin, R. J. M., & Goldman, J. E. (2004) · Elsevier eBooks · doi:10.1016/b978-012439510-7/50060-7 · Cited by 17
Cryptic Axonal Antigens and Axonal Loss in Multiple Sclerosis
DeVries, G. H. (2004) · Neurochemical Research · doi:10.1007/s11064-004-6873-1 · Cited by 15
“Since premyelinating oligodendrocytes are found in MS lesions (32), the axolemma antibodies may block crucial axon-oligodendrocyte precursor interactions, which are necessary for remyelination (Figure 2).”
BackgroundTNFα: kill or cure for demyelinating disease?
Finsen, B. R., Antel, J. P., & Owens, T. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001120 · Cited by 15
Multiple Sclerosis and Other Acquired Demyelinating Diseases of the Central Nervous System
Kornberg, M. D., & Calabresi, P. A. (2024) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041374 · Cited by 18
Kitzler, H. H., Wahl, H., Kuntke, P., Deoni, S., Ziemssen, T., Linn, J., & Köhler, C. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103192 · Cited by 15
“Besides this evidence of repair in early inflammatory active lesions even chronic MS lesions revealed remyelination (Chang et al., 2002).”
Aerobic exercise attenuates abnormal myelination and oligodendrocyte differentiation in 3xTg-AD mice
Qiu, D., Zhou, S., Donnelly, J., Xia, D., & Zhao, L. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112293 · Cited by 14
“Similar effects have been reported in studies of chronic multiple sclerosis lesions where OPCs were impaired in migration and differentiation, leading to insufficient remyelination (Chang et al., 2002; Franklin, 2002; Kuhlmann et al., 2008).”
Nuclear receptor PPARγ targets GPNMB to promote oligodendrocyte development and remyelination
Han, B., Bao, M.-Y., Sun, Q., Wang, R., Deng, X., Xing, K., Yu, F.-L., Zhang, Y., Li, X., Li, X.-Q., et al. (2024) · Brain · doi:10.1093/brain/awae378 · Cited by 16
Thrombin generation and activity in multiple sclerosis
Jordan, K. R., Parra‐Izquierdo, I., Gruber, A., Shatzel, J. J., Pham, P. T., Sherman, L. S., McCarty, O. J. T., & Verbout, N. G. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-020-00652-w · Cited by 14
Nakahara, J., Aiso, S., & Suzuki, N. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903307491 · Cited by 14
“These results were further confirmed with several other markers, including NG2, Olig1, Olig2, and FcRg/Olig2 [33-37], and it is now established that OPCs and occasionally immature oligodendrocytes [38] are preserved in many, if not all, MS lesions, even in the chronic phase.”
BackgroundResultRecruitment of endogenous CNS stem cells for regeneration in demyelinating disease
Murphy, N. A., & Franklin, R. J. M. (2017) · Progress in brain research · doi:10.1016/bs.pbr.2016.12.013 · Cited by 15
“…step of remyelination with aging—a hypothesis further strengthened by the existence of chronic MS lesions with OPCs and preoligodendrocytes seemingly unable to differentiate or myelinate (Chang et al., 2002; 142 CHAPTER 6 Endogenous CNS stem cells in demyelinating disease Kuhlmann et al., 2008).”
BackgroundAhrendsen, J. T., Harlow, D. E., Finseth, L. T., Bourne, J. N., Hickey, S. P., Gould, E. A., Culp, C. M., & Macklin, W. B. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.2864-16.2017 · Cited by 15
“Furthermore, the role of Shp2 in regulating oligodendrocyte differentiation following demyelination has important therapeutic implications, as differentiation failure is a pathological feature in multiple sclerosis and thought to contribute to remyelination failure as the disease progresses (Chang et al., 2002).”
BackgroundNanopore Fabrication and Application as Biosensors in Neurodegenerative Diseases
Lenhart, B. J., Wei, X., Zhang, Z., Wang, X., Wang, Q., & Liu, C. (2020) · Critical Reviews in Biomedical Engineering · doi:10.1615/critrevbiomedeng.2020033151 · Cited by 16
Kumar, N., Singh, V. P., Li, L., Willard, B. B., Tripathi, A. K., & Dutta, R. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.779003 · Cited by 15
“Active demyelinating white-matter lesions (WMLs, with abundant microglia/macrophages containing myelin degradation products) are commonly found in relapsing-remitting (RR) patients, while GRAPHICAL ABSTRACT | Graphical summary of the main findings of the study. inactive or chronic active demyelinating lesions with a r…”
InfluentialZhang, T., Alonzo, I. G., Stubben, C., Geng, Y., Herdman, C., Chandler, N., Doane, K. P., Pluimer, B. R., Trauger, S. A., & Peterson, R. T. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.049995 · Cited by 15
Foerster, S., Neumann, B., McClain, C. R., Canio, L. D., Chen, C. Z.-Y., Reich, D. S., Simons, B. D., & Franklin, R. J. M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.21.108373 · Cited by 15
“, 2013), contain sufficient numbers of oligodendrocyte lineage cells, which seem to be arrested in their differentiation (Chang et al., 2002; Kuhlmann et al., 2008).”
BackgroundNewsome, S. D., Tian, F., Shoemaker, T., Fitzgerald, K. C., Cassard, S. D., Fiol, J., Snoops, S., Cooper, D. S., Mammen, J. S., Bhargava, P., et al. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01402-3 · Cited by 13
“1 3 oligodendrocytes, which suggest that failed remyelination does occur and could be partially due to incomplete oligodendrocyte differentiation [8].”
BackgroundSajad, M., Zahoor, I., Rashid, F., Cerghet, M., Rattan, R., & Giri, S. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03546-x · Cited by 13
He, Y., An, J., Yin, J.-J., Miao, Q., Sui, R., Han, Q.-X., Ding, Z., Huang, J., Ma, C., & Xiao, B. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00947-x · Cited by 17
Anastasiadou, S., Liebenehm, S., Sinske, D., zu Reckendorf, C. M., Moepps, B., Nordheim, A., & Knöll, B. (2015) · Glia · doi:10.1002/glia.22794 · Cited by 15
“NG2-positive OPCs represent a third cell type present in demyelinated brain (Chang et al. 2002).”
BackgroundShimizu, T., Tanaka, K. F., Takebayashi, H., Higashi, M., Durose, W. W., Ono, K., Hitoshi, S., & Ikenaka, K. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23153 · Cited by 14
“In chronic lesions of the Plptg/2 brain, Olig21 and PDGFRa1 OPCs and PLP1 premyelinating OLs are abundant, yet they do not progress toward remyelination (Ma et al., 2006).”
BackgroundMethodResultInfluentialLevy-Amir, Y., Mausner-Fainberg, K., & Karni, A. (2014) · Multiple Sclerosis International · doi:10.1155/2014/926134 · Cited by 16
“Experimental Autoimmune Encephalomyelitis via Induction of”
Replacing cells in multiple sclerosis
Duncan, I. D. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.04.043 · Cited by 13
“It appears that OPCs within such a chronic plaque differentiate poorly or if they do, are unable to normally ensheathe and remyelinate axons [14,15].”
Peripheral Inflammation and Demyelinating Diseases
Murta, V., & Ferrari, C. C. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-40764-7_13 · Cited by 15
Myelin failure in multiple sclerosis: Breaking the spell of Notch
Hohlfeld, R. (2002) · Nature Medicine · doi:10.1038/nm1002-1075 · Cited by 13
“and obstruction of oligodendrocytes by astrocytic scarring; and 3) reduced receptiveness of injured axons to remyelinatio”
BackgroundRashidbenam, Z., Öztürk, E., Pagnin, M., Theotokis, P., Grigoriadis, N., & Petratos, S. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1197492 · Cited by 12
Yoshida, A., Takashima, K., Shimonaga, T., Kadokura, M., Nagase, S., & Koda, S. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108798 · Cited by 12
Wootla, B., Watzlawik, J. O., Đenić, A., & Rodriguez, M. (2013) · Expert Review of Clinical Immunology · doi:10.1586/eci.13.37 · Cited by 12
Axonal activity-dependent myelination in development: Insights for myelin repair
Mitew, S., Xing, Y. L., & Merson, T. D. (2016) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2016.03.002 · Cited by 12
Catalpol induces oligodendrocyte precursor cell-mediated remyelination in vitro.
Yuan, C.-X., Chu, T., Liu, L., Li, H., Wang, Y., Guo, A., & Fan, Y. (2015) · PubMed · Cited by 13
Taking Advantage of Nature’s Gift: Can Endogenous Neural Stem Cells Improve Myelin Regeneration?
Akkermann, R., Jadasz, J. J., Azim, K., & Küry, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111895 · Cited by 14
“Whilst OPCs can be detected in and around MS lesions, they often fail to differentiate, probably due to the presence of multiple differentiation-associated inhibitors, which prevent the generation of remyelinating OLs [12,21–26].”
BackgroundAATYK is a Novel Regulator of Oligodendrocyte Differentiation and Myelination
Jiang, C., Yang, W., Fan, Z., Teng, P., Mei, R., Yang, J., Yang, A., Qiu, M. S., & Zhao, X. (2018) · Neuroscience Bulletin · doi:10.1007/s12264-018-0218-6 · Cited by 12
Remyelination strategies: New advancements toward a regenerative treatment in multiple sclerosis
Stangel, M., & Trebst, C. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-006-0010-2 · Cited by 17
The K2P‐channel TASK1 affects Oligodendroglial differentiation but not myelin restoration
Albrecht, S., Korr, S., Nowack, L., Narayanan, V., Starost, L. J., Stortz, F., Araúzo-Bravo, M. J., Meuth, S. G., Kuhlmann, T., & Hundehege, P. (2019) · Glia · doi:10.1002/glia.23577 · Cited by 12
Papadopoulou, A., Menegola, M., Kühle, J., Ramagopalan, S. V., D’Souza, M., Sprenger, T., Radue, E. W., Kappos, L., & Yaldizli, Ö. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513495583 · Cited by 12
Perdaens, O., & Pesch, V. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312637 · Cited by 13
Demyelination and Remyelination in Multiple Sclerosis
Bø, L., Esiri, M. M., Evangelou, N., & Kuhlmann, T. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2218-1_2 · Cited by 13
The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of in vitro and in vivo Models
Ainatzoglou, A., Stamoula, Ε., Dardalas, I., Siafis, S., & Papazisis, G. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210303142356 · Cited by 11
Merour, E., Hmidan, H., Marie, C., Helou, P.-H., Lu, H., Potel, A., Huré, J.-B., Clavairoly, A., Shih, Y. P., Goudarzi, S., et al. (2022) · eLife · doi:10.7554/elife.80273 · Cited by 13
Theotokis, P., Kesidou, E., Mitsiadou, D., Petratos, S., Damianidou, O., Boziki, M. K., Chatzidimitriou, A., & Grigoriadis, N. (2021) · Brain Pathology · doi:10.1111/bpa.13040 · Cited by 11
“However, in multifocal neuroinflammatory diseases such as MS, restoration of myelin and prevention of secondary degeneration would require a sufficient dissemination of cells, because resident OPCs closer to the lesions are not always capable of activating their regenerating properties and they remain in a quiescent s…”
BackgroundFillatreau, S., & Anderton, S. M. (2007) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.3.4.565 · Cited by 12
The association between multiple sclerosis and spondylosis: When and why
Xydis, V. G., Zikou, A. K., Kostadima, V., Astrakas, L. G., Kosta, P., & Argyropoulou, M. I. (2017) · European Journal of Radiology · doi:10.1016/j.ejrad.2017.03.017 · Cited by 11
“As the disease progresses remyelination becomes less efficient and finally fails [26, 27].”
BackgroundActivation of FXR pathway does not alter glial cell function
Albrecht, S., Fleck, A.-K., Kirchberg, I. E., Hucke, S., Liebmann, M., Klotz, L., & Kuhlmann, T. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0833-6 · Cited by 11
Hoch-Kraft, P., Trotter, J., & Gonsior, C. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02763-y · Cited by 13
Stem Cell Biology in Health and Disease
Dittmar, T., & Zänker, K. S. (2009) · Springer eBooks · doi:10.1007/978-90-481-3040-5 · Cited by 12
Fressinaud, C., & Eyer, J. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.012 · Cited by 11
“, 2005), which might, in turn, render axons unproper for remyelination (Chang et al., 2002).”
BackgroundGeneration and potential biomedical applications of embryonic stem cell-derived glial precursors
Glaser, T., Schmandt, T., & Brüstle, O. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.09.018 · Cited by 12
“Another important fact to consider is that many MS plaques are populated with OPCs that appear unable to differentiate and form myelin [169,170], suggesting that regions of demyelination lack the appropriate signals for remyelination — a deficit, which could also impact on transplanted myelin-forming cells.”
BackgroundRipa, I., Andreu, S., Josa‐Prado, F., Fernández‐Gómez, B., de Castro, F., Arribas, M., Bello‐Morales, R., & López‐Guerrero, J. A. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1411655 · Cited by 10
Gobbo, D., Rieder, P., Fang, L., Buttigieg, E., Schablowski, M., Damo, E., Bosche, N., Dallorto, E., May, P., Bai, X., et al. (2024) · Cells · doi:10.3390/cells13232014 · Cited by 11
Impaired remyelination in late-onset multiple sclerosis
Stork, L., Stephan, S., Kutllovci, A., Brück, W., & Metz, I. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02868-5 · Cited by 10
Metadata
- Authors
- Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D.
- Affiliations
- Cleveland Clinic (US)
- VA West Los Angeles Medical Center (US)
- Cleveland Clinic Research (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-01-17
- Volume
- 346
- Issue
- 3
- Pages
- 165-173
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2058358434
- Cited by
- 991
- References
- 39
- Citations by year
- 2026: 19 · 2025: 25 · 2024: 42 · 2023: 38 · 2022: 32 · 2021: 34 · 2020: 36 · 2019: 57 · 2018: 43 · 2017: 52 · 2016: 44 · 2015: 55 · 2014: 44 · 2013: 50 · 2012: 40
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (R01 NS35058, P01NS038667, R01NS035058, P01-NS-38667)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- multiple sclerosis, remyelination, chronic lesions, demyelinated axons, oligodendrocyte precursor cells, disease duration
- MeSH terms
- Chondroitin Sulfate Proteoglycan 4, Adult, Aged, Antigens, Axons, Brain, Brain Chemistry, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Nerve Fibers, Myelinated, Oligodendroglia, Proteoglycans, Stem Cells, Microscopy, Confocal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.